PRESS RELEASE published on 06/03/2026 at 19:54, 4 months 26 days ago Inside Information / Other news releases Median Technologies successfully completes €50 million capital increase without shareholders' preferential subscription rights. Funds to deploy eyonis® LCS in U.S. and Europe and expand clinical indications Investment Capital Increase Median Technologies Eyonis® LCS Clinical Indications
BRIEF published on 05/21/2026 at 17:50, 5 months 8 days ago Median Technologies publie les documents de l'assemblée générale des actionnaires Droit De Vote Euronext Croissance Assemblée Générale Des Actionnaires Technologies Médianes Disponibilité Des Documents
BRIEF published on 05/21/2026 at 17:50, 5 months 8 days ago Median Technologies Publishes Shareholder Meeting Documents Voting Rights Shareholders’ Meeting Euronext Growth Median Technologies Documents Availability
PRESS RELEASE published on 05/21/2026 at 17:45, 5 months 8 days ago Terms of availability of the information and the report on corporate governance Median Technologies releases preparatory documents for the Annual Shareholders’ Meeting on June 10, 2026. Shareholders can access documents on the company's website Shareholders General Meeting Annual Shareholders’ Meeting Preparatory Documents Median Technologies
BRIEF published on 03/30/2026 at 15:19, 6 months 30 days ago Median Technologies obtient la certification ISO 13485:2016 ISO 13485:2016 Normes Réglementaires Logiciel Basé Sur L'IA Solutions En Oncologie Eyonis®
BRIEF published on 03/30/2026 at 15:19, 6 months 30 days ago Median Technologies Achieves ISO 13485:2016 Certification ISO 13485:2016 Regulatory Standards Oncology Solutions Eyonis® AI-based SaMD
PRESS RELEASE published on 03/30/2026 at 15:14, 6 months 30 days ago Inside Information / Other news releases Median Technologies achieves ISO 13485:2016 certification for eyonis® Medical Device Quality Management System, reinforcing commitment to safe and reliable oncology solutions Median Technologies AI-based Software Oncology Solutions ISO 13485:2016 Certification Eyonis Medical Device
BRIEF published on 02/12/2026 at 22:10, 8 months 17 days ago Median Technologies and Tempus Partner to Expand Lung Cancer Screening in the U.S. FDA Clearance Median Technologies Lung Cancer Screening Eyonis® LCS Tempus AI
BRIEF published on 02/12/2026 at 22:10, 8 months 17 days ago Median Technologies et Tempus s'associent pour étendre le dépistage du cancer du poumon aux États-Unis. Autorisation De La FDA Technologies Médianes Dépistage Du Cancer Du Poumon Eyonis® LCS Tempus IA
PRESS RELEASE published on 02/12/2026 at 22:05, 8 months 17 days ago Informations privilégiées / Autres communiqués Median Technologies collabore avec Tempus pour distribuer le logiciel eyonis® LCS aux États-Unis, suite à l'obtention de l'autorisation FDA 510(k) pour le dépistage du cancer du poumon via Tempus Pixel Median Technologies Eyonis® LCS Tempus FDA 510(k) Dépistage Cancer
Published on 10/30/2026 at 12:00, 27 minutes ago Aztec Minerals Strengthens Technical Management Team
Published on 10/29/2026 at 22:01, 14 hours 26 minutes ago Pinetree Capital Announces Unaudited Financial Results for the Period Ended September 30, 2026
Published on 10/29/2026 at 21:30, 14 hours 57 minutes ago Shelfie Announces Amendments to Previously Announced Acquisition of Aspect
Published on 10/29/2026 at 18:30, 17 hours 57 minutes ago Kidoz Inc. Appoints Derek Sentner as Chief Revenue Officer
Published on 10/30/2026 at 12:11, 15 minutes ago EQS-Adhoc: FRIWO AG: FRIWO adjusts forecast for 2026 due to persistent market weakness downward – growth stimulus from the order backlog and project pipeline
Published on 10/30/2026 at 12:00, 27 minutes ago Kapitaalverhoging door uitoefening van inschrijvingsrechten
Published on 10/30/2026 at 12:00, 27 minutes ago Capital increase through exercise of subscription rights
Published on 10/30/2026 at 08:00, 4 hours 27 minutes ago Neoen secures AUD 1.8 billion in debt financing to support renewable energy portfolio in Australia
